Englander Institute for Precision Medicine
Found 797 results
Author Title Type [ Year(Desc)]
Filters: Clinical-trials-corner-issue-10(1) is   [Clear All Filters]
2022
Batra R, Uni R, Akchurin OM, Alvarez-Mulett S, Gómez-Escobar LG, Patino E, Hoffman KL, Simmons W, Chetnik K, Buyukozkan M et al..  2022.  Urine-based multi-omic comparative analysis of COVID-19 and bacterial sepsis-induced ARDS.. medRxiv.
Malla M, Loree JM, Kasi PMurtaza, Parikh ARaj.  2022.  Using Circulating Tumor DNA in Colorectal Cancer: Current and Evolving Practices.. J Clin Oncol. 40(24):2846-2857.
Rajappa P, Eng KW, Bareja R, Bander ED, Yuan M, Dua A, Maachani UBhanu, Snuderl M, Pan H, Zhang T et al..  2022.  Utility of multimodality molecular profiling for pediatric patients with central nervous system tumors.. Neurooncol Adv. 4(1):vdac031.
Gomari DP, Schweickart A, Cerchietti L, Paietta E, Fernandez H, Al-Amin H, Suhre K, Krumsiek J.  2022.  Variational autoencoders learn transferrable representations of metabolomics data.. Commun Biol. 5(1):645.
Brendel M, Getseva V, Assaad MAl, Sigouros M, Sigaras A, Kane T, Khosravi P, Mosquera JMiguel, Elemento O, Hajirasouliha I.  2022.  Weakly-supervised tumor purity prediction from frozen H&E stained slides.. EBioMedicine. 80:104067.
Barratt CLR, Wang C, Baldi E, Toskin I, Kiarie J, Lamb DJ.  2022.  What advances may the future bring to the diagnosis, treatment, and care of male sexual and reproductive health? Fertil Steril. 117(2):258-267.
Turco F, Armstrong A, Attard G, Beer TM, Beltran H, Bjartell A, Bossi A, Briganti A, Bristow RG, Bulbul M et al..  2022.  What Experts Think About Prostate Cancer Management During the COVID-19 Pandemic: Report from the Advanced Prostate Cancer Consensus Conference 2021.. Eur Urol. 82(1):6-11.
De Giorgi U, Hussain M, Shore N, Fizazi K, Tombal B, Penson D, Saad F, Efstathiou E, Madziarska K, Steinberg J et al..  2022.  Which traits affect how long patients with advanced prostate cancer live when treated with enzalutamide? Future Oncol. 18(35):3867-3874.
Lobo J, Ohashi R, Amin MB, Berney DM, Compérat EM, Cree IA, Gill AJ, Hartmann A, Menon S, Netto GJ et al..  2022.  WHO 2022 landscape of papillary and chromophobe renal cell carcinoma.. Histopathology. 81(4):426-438.
Cyrta J, Rosiene J, Bareja R, Kudman S, Zoughbi WAl, Motanagh S, Wilkes DC, Eng K, Zhang T, Sticca E et al..  2022.  Whole-genome characterization of myoepithelial carcinomas of the soft tissue.. Cold Spring Harb Mol Case Stud. 8(7)
Santambrogio L, Franco A.  2022.  The yin/yang balance of the MHC-selfimmunopeptidome.. Front Immunol. 13:1035363.
2023
Weinstock JS, Gopakumar J, Burugula BBharathi, Uddin MMesbah, Jahn N, Belk JA, Bouzid H, Daniel B, Miao Z, Ly N et al..  2023.  Aberrant activation of TCL1A promotes stem cell expansion in clonal haematopoiesis.. Nature. 616(7958):755-763.
Kasi PMurtaza, Afable MGeroy, Herting C, Lukanowski M, Jin Z.  2023.  Anti-EGFR Antibodies in the Management of Advanced Colorectal Cancer.. Oncologist. 28(12):1034-1048.
Vitale I, Pietrocola F, Guilbaud E, Aaronson SA, Abrams JM, Adam D, Agostini M, Agostinis P, Alnemri ES, Altucci L et al..  2023.  Apoptotic cell death in disease-Current understanding of the NCCD 2023.. Cell Death Differ. 30(5):1097-1154.
Mak L, Meleshko D, Danko DC, Barakzai WN, Maharjan S, Belchikov N, Hajirasouliha I.  2023.  Ariadne: synthetic long read deconvolution using assembly graphs.. Genome Biol. 24(1):197.
Johnson JL, Yaron TM, Huntsman EM, Kerelsky A, Song J, Regev A, Lin T-Y, Liberatore K, Cizin DM, Cohen BM et al..  2023.  An atlas of substrate specificities for the human serine/threonine kinome.. Nature. 613(7945):759-766.
Khani F, Hooper WF, Wang X, Chu TR, Shah M, Winterkorn L, Sigouros M, Conteduca V, Pisapia D, Wobker S et al..  2023.  Author Correction: Evolution of structural rearrangements in prostate cancer intracranial metastases.. NPJ Precis Oncol. 7(1):113.
Hsiehchen D, Bucheit L, Yang D, Beg MShaalan, Lim M, Lee SS, Kasi PMurtaza, Kaseb AO, Zhu H.  2023.  Author Correction: Genetic features and therapeutic relevance of emergent circulating tumor DNA alterations in refractory non-colorectal gastrointestinal cancers.. Nat Commun. 14(1):7621.
Santambrogio L.  2023.  Autoimmunity to the modified self.. Science. 379(6637):1092-1093.
Powles T, Park SHoon, Caserta C, Valderrama BP, Gurney H, Ullén A, Loriot Y, Sridhar SS, Sternberg CN, Bellmunt J et al..  2023.  Avelumab First-Line Maintenance for Advanced Urothelial Carcinoma: Results From the JAVELIN Bladder 100 Trial After ≥2 Years of Follow-Up.. J Clin Oncol. 41(19):3486-3492.
Grivas P, Park SHoon, Voog E, Caserta C, Gurney H, Bellmunt J, Kalofonos H, Ullén A, Loriot Y, Sridhar SS et al..  2023.  Avelumab First-line Maintenance Therapy for Advanced Urothelial Carcinoma: Comprehensive Clinical Subgroup Analyses from the JAVELIN Bladder 100 Phase 3 Trial.. Eur Urol. 84(1):95-108.
Grivas P, Grande E, Davis ID, Moon HH, Grimm M-O, Gupta S, Barthélémy P, Thibault C, Guenther S, Hanson S et al..  2023.  Avelumab first-line maintenance treatment for advanced urothelial carcinoma: review of evidence to guide clinical practice.. ESMO Open. 8(6):102050.
Hajirasouliha I, Semrau S.  2023.  Back in 3D-a report on Genome Informatics 2022.. Genome Biol. 24(1):57.
Boeck N, Trajanoski Z, Galluzzi L.  2023.  Bacterial antigens unleash tumor-targeting immunity.. Cell Host Microbe. 31(12):1945-1947.
Zhao L, Liu P, Mao M, Zhang S, Bigenwald C, Dutertre C-A, Lehmann CHK, Pan H, Paulhan N, Amon L et al..  2023.  BCL2 Inhibition Reveals a Dendritic Cell-Specific Immune Checkpoint That Controls Tumor Immunosurveillance.. Cancer Discov. 13(11):2448-2469.